Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
about
Update on Mucin-1 immunotherapy in cancer: a clinical perspective.Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response.Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.
P2860
Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Yeast virus-derived stimulator ...... us vector-based immunotherapy.
@en
Yeast virus-derived stimulator ...... us vector-based immunotherapy.
@nl
type
label
Yeast virus-derived stimulator ...... us vector-based immunotherapy.
@en
Yeast virus-derived stimulator ...... us vector-based immunotherapy.
@nl
prefLabel
Yeast virus-derived stimulator ...... us vector-based immunotherapy.
@en
Yeast virus-derived stimulator ...... us vector-based immunotherapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Yeast virus-derived stimulator ...... rus vector-based immunotherapy
@en
P2093
Caroline Tosch
Christelle Remy-Ziller
Emmanuelle Schaedler
Jean-Baptiste Marchand
Jean-Yves Bonnefoy
Julie Hortelano
Karola Rittner
Laurence Laruelle
Marie-Christine Claudepierre
Michel Geist
P2860
P304
P356
10.1128/JVI.03819-13
P407
P577
2014-02-26T00:00:00Z